Founded in 2020, eMedicals Healthtech operates at the intersection of biosciences and healthtech, developing a plant biochemical platform for novel therapeutics while also pioneering next generation AI analytics and biomarkers for Chronic Kidney Disease (CKD) and Cardiometabolic Diseases.
Through our advanced R&D results, eMedicals secured funding in 2021 from prestigious research excellence programs supported by the German Federal Ministry of Education and Research and the Hessian Ministry of Science and Art.
In 2022, we further strengthened our position by securing equity investment from industry-expert angel investors and obtaining a substantial bank loan, underscoring the robust support for our innovative approach.
Our plant-based platform
Based on our holistic approach, we are able to offer a wide range of services for hospitals, insurers and pharma within the ecosystem of CKD and Cardiometabolic diseases.
Providing Value for multiple stakeholders
Patients
Our platform patients to synergistically manage their medication, diet, and health data, helping to reduce pill and injectable use, shorten hospital stays, and delay the need for dialysis.
Clinicians
Our Clinical Decision Support System (CDSS) streamlines doctors' daily workflows and enhances the quality of therapy decisions through advanced medical visual analytics tools.
Insurers
Our products have the potential to generate significant cost savings by reducing medication, hospitalisation or dialysis treatment.
Pharma
We aim to provide an innovative plant-based drug production and delivery system that utilizes plant matrices to deliver active pharmaceutical ingredients, improving medication efficacy and patient adherence.
Slowing down progression of Nutrition-sensitive diseases (CKD,T2D,CVD) through nutrigenomics by building and applying Neuro-Symbolic AI technologies